Pharma Business of HIV/AIDS, STDs & STIs

Global HIV Drug Market was valued at $20,448 million in 2015 and is expected to increase till $26,458 million by 2022, registering a CAGR of 3.7% during the forecast period 2016-2022. Human immunodeficiency virus (HIV) is one of the most infectious diseases with around 36.7 million people suffering by the end of 2015. The major factors that boost the HIV drug market growth include increase in prevalence of HIV and rise in treatment & diagnosis rate. Moreover, there is an increase in the government initiative to increase awareness among people about HIV cause, symptoms, available treatment options, and the crucial role of these treatments in the control of HIV virus growth. Thus, rise in awareness through such government initiatives are also expected to drive the HIV drugs market. However, a stringent government regulation for the approval and commercialization of HIV drugs is expected to restrain the industry growth.

    Related Conference of Pharma Business of HIV/AIDS, STDs & STIs

    October 24-25, 2022

    17th World Congress on Virology, Emerging Diseases & Vaccines

    Zurich, Switzerland
    November 08-09, 2022

    7th Rare Diseases and Orphan Drugs

    London, UK
    November 21-22, 2022

    World Summit on Rare Disease

    Rome, Italy
    December 12-13, 2022

    5th Pathology and Infectious Disease Conference

    Prague, Czech Republic
    January 23-24, 2023

    10th International Congress on Infectious Diseases

    Barcelona, Spain
    February 20-21, 2023

    6th International Conference on Rare Diseases

    Amsterdam, Netherlands
    August 08-09, 2023

    19th World Congress on Infection Prevention and Control

    Zurich, Switzerland

    Pharma Business of HIV/AIDS, STDs & STIs Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in